Active Ingredient History

  • Now
Safinamide (FCE 26743, NW 1015, PNU 151774, PNU 151774E, trade name Xadago) combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide is under development with Newron, Zambon and Meiji Seika Pharma for the treatment of Parkinson's disease. Safinamide has been launched in the EU, Iceland and Liechtenstein. Safinamide was well tolerated and safe in the clinical development program that demonstrated the amelioration of motor symptoms and OFF phenomena by safinamide when combined with dopamine agonists or levodopa.   NCATS

  • SMILES: C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(=O)N
  • Mol. Mass: 302.35
  • ALogP: 2.37
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)


$1.3529 - $2.7058

United States

$20.8900 - $29.0395
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-(4-(3-fluorobenzyloxy)benzylamino)propionamide | emd 1195686 | emd-1195686 | fbap methanesulfonate | fce 26743 | fce-26743 | fce 28073 | fce-28073 | nw-1015 | pnu 151774e | pnu-151774e | (s)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide | safinamide | safinamide mesilate | safinamide mesylate | safinamide methanesulfonate | safinimide | xadago


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue